HoldsUp

Anurag Singh

Dr. Anurag Singh is an immunologist and mitochondrial longevity scientist. His research focuses on the effects of the postbiotic and mitophagy inducer Urolithin A. His published studies investigate Urolithin A's impact on age-related immune decline, cardiovascular health biomarkers, and athletic performance and recovery.

34 claims checked on air: 2 context 1 contradicted 7 overstated 20 supported 4 unverified 8 flagged

What they said on air - citing their own research

5 citing their own research

0:47:09overstatedlowtheir own paperLongevity Scientist: Can This Supplement Really Reverse Agin

Clinical trials of urolithin A across sedentary older adults, overweight individuals, and elite athletes consistently demonstrate reductions in C-reactive protein, interleukin-1 beta, and TNF-alpha alongside improved mitochondrial health.

"The early trials we did, as I mentioned, whether it was the older adults, you know, sitting on their couch potato, not getting to move, or the overweight folks, or even the elite athletes, the hallmarks—whenever we would see improved mitochondrial health, in the background we would always see lowering of C-reactive protein, we would always see lowering of interleukin-1 beta or TNF-alpha." (said at 0:47:09)

Randomized controlled trials evaluating urolithin A in humans (including older adults and trained endurance athletes) have shown preliminary signals of mitochondrial modulation and proteomic downregulation of inflammatory pathways. However, claiming that trials across sedentary older adults, overweight individuals, and elite athletes 'consistently demonstrate' or 'always' show significant reductions in C-reactive protein (CRP), interleukin-1 beta (IL-1β), and TNF-α overstates the published evidence. A systematic review of human trials notes that clinical evidence remains preliminary across small cohorts (n = 236 across five trials), with mitochondrial and inflammatory biomarkers showing heterogeneous, exploratory outcomes rather than established, consistent efficacy.

0:47:42supportedmoderatetheir own paperLongevity Scientist: Can This Supplement Really Reverse Agin

A clinical trial administering urolithin A for one month to healthy 40- to 50-year-olds profiling over 80 immune populations showed an increase in age-declining immune cells (such as T cells and NK cells) containing higher numbers of mitochondria and enhanced pathogen-killing capacity.

"And he said, 'Well, let's do a trial where we give this molecule for a month to healthy 40, 50-year-olds and we look at every single immune cell in the body, at the impact it's causing and the mitochondria in it.'... What we actually now find with supplementation is that a lot of these immune cells that are declining with aging, they come back with Mitopure supplementation. And when they come back, they have more mitochondria... And these immune cells are more wired to fight infection. So if you throw an infection on them, they engulf it and kill it much faster." (said at 0:47:42)

A double-blind, randomized, placebo-controlled clinical trial in 50 healthy middle-aged adults evaluated 4 weeks (1 month) of oral urolithin A (1,000 mg/day) supplementation. The trial found that urolithin A supplementation expanded naive-like CD8+ T cells and peripheral NK cell subsets, augmented mitochondrial biogenesis in CD8+ T cells, improved T-cell cytokine activation, and enhanced bacterial phagocytosis (uptake) in monocytes.

1:29:16supportedvery lowtheir own paperLongevity Scientist: Can This Supplement Really Reverse Agin

In animal models of heart failure, Mitopure (Urolithin A) supplementation reversed cardiac damage by improving mitochondrial health.

"we went into models of heart failure, acute and chronic, and we found that giving Mitopure supplementation in these models reversed a lot of this cardiac damage by improving mitochondrial health." (said at 1:29:16)

Preclinical studies in animal models of heart failure and cardiac aging support the claim. Research shows that Urolithin A (Mitopure) supplementation reduces cardiac dysfunction, hypertrophy, and fibrosis while restoring mitochondrial ultrastructure, respiration, and mitophagy. Because these findings are established in animal and cellular models, the certainty of evidence for clinical human efficacy in heart failure remains very low.

1:30:00supportedmoderatetheir own paperLongevity Scientist: Can This Supplement Really Reverse Agin

In clinical trials, Mitopure supplementation reduces plasma levels of ceramides in humans.

"And what we see is actually in all our trials, plasma levels of ceramides are going down." (said at 1:30:00)

Randomized controlled trials evaluating urolithin A (Mitopure) supplementation in older adults have demonstrated reductions in circulating plasma ceramide levels. In a double-blind, placebo-controlled clinical trial (PMID 35050355), four months of oral urolithin A supplementation significantly decreased plasma levels of several ceramides, acylcarnitines, and C-reactive protein compared with placebo. Subsequent analyses and human trials (PMID 40034121) similarly report that four months of urolithin A supplementation reduces cardiovascular-risk-associated plasma ceramides.

1:30:50supportedmoderatetheir own paperLongevity Scientist: Can This Supplement Really Reverse Agin

Mitopure (Urolithin A) supplementation improves VO2 max in humans.

"But we do know things like VO2 max improve with Mitopure, which is also cardiovascular health." (said at 1:30:50)

A double-blind, randomized, placebo-controlled trial evaluating Urolithin A (Mitopure) supplementation in middle-aged adults demonstrated improvements in aerobic endurance measured by peak oxygen consumption (peak VO2) and 6-minute walk distance, alongside improvements in muscle strength and mitochondrial biomarkers. In trained male distance runners, supplementation also led to significant within-group increases in VO2 max, although between-group differences compared to placebo during altitude training camp did not reach statistical significance.

Fact-checked episodes

Publications